Virus therapy fails to advance in colorectal cancer trial
NCT ID NCT05733611
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early after enrolling only 5 participants. The goal was to see if the combination could shrink tumors, but results are limited due to early termination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MICROSATELLITE STABLE COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Washington Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Can a Triple-Drug rechallenge tame colorectal cancer?
- New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
- New hope for Tough-to-Treat colorectal cancer: drug targets specific protein
- New combo therapy aims to boost survival in tough rectal cancer
- New cocktail aims to shrink rectal tumors before surgery